Detalles de la búsqueda
1.
Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts.
J Pharmacol Exp Ther
; 366(1): 96-104, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29691287
2.
Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.
J Pharmacol Exp Ther
; 360(3): 445-456, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28028124
3.
Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.
Blood
; 121(18): 3675-81, 2013 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23509154
4.
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.
Int J Toxicol
; 31(4): 317-25, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22692976
5.
Addressing Unusual Assay Variability with Robust Statistics.
SLAS Discov
; 26(10): 1291-1297, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34474612
6.
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Oncotarget
; 11(3): 216-236, 2020 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32076484
7.
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
AAPS J
; 21(2): 23, 2019 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706160
8.
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Clin Cancer Res
; 25(7): 2278-2289, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563935
9.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Cancer Discov
; 9(2): 248-263, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373917
10.
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
Eur J Pharm Sci
; 115: 296-303, 2018 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29366960
11.
Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29866156
12.
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models.
Sci Rep
; 8(1): 15458, 2018 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30337562
13.
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Cell Rep
; 22(11): 2978-2994, 2018 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29539425
14.
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-ß receptor type I inhibitor.
Oncotarget
; 9(6): 6659-6677, 2018 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29467918
15.
Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery.
Clin Transl Sci
; 11(5): 461-470, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29877628
16.
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Cancer Res
; 65(16): 7462-9, 2005 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16103100
17.
Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
Cancer Res
; 65(15): 6593-600, 2005 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16061639
18.
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.
Clin Cancer Res
; 23(18): 5547-5560, 2017 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28611205
19.
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Cancer Cell
; 32(6): 761-776.e6, 2017 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29232554
20.
A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio.
J Biomol Screen
; 11(3): 247-52, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16490779